GlassScriptPhysician profile
Mary Beth E Richmond
NPI 1215032826
$5,058.23
in general payments reported to CMS, 2019-2025
25 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,197 · 2020: $230 · 2021: $38.05 · 2022: $468 · 2023: $983 · 2024: $1,085 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,125.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,071.54 | 2019-2025 | |
| Novo Nordisk INC | $811.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $517.67 | 2019-2025 | Repatha, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.38 | 2019-2025 | Jardiance |
| Abbvie INC. | $331.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $324.05 | 2019-2025 | Farxiga, Fasenra |
| Janssen Pharmaceuticals, INC | $188.25 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $168.21 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $151.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $150.19 | 2019-2024 | |
| Glaxosmithkline, LLC. | $146.33 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $134.76 | 2023-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $131.26 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $115.22 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $78.50 | 2019-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.59 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $30.34 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $28.95 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $24.12 | 2025 | Aptima |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.92 | 2025 | Xifaxan |
| Astellas Pharma US INC | $22.55 | 2019 | |
| Medtronic USA, INC. | $19.78 | 2019 | |
| Bausch Health US, LLC | $18.40 | 2019 | |
| Sanofi Pasteur INC. | $18.00 | 2019 | |
| Ibsa Pharma INC. | $17.45 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beth Richmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.